コンテンツへスキップ
Merck

B0470000

Benperidol

European Pharmacopoeia (EP) Reference Standard

別名:

1-{1-[4-(4-Fluorophenyl)-4-oxobutyl]-piperidin-4-yl}-1,3-dihydro-benzimidazol-2-one

ログイン組織・契約価格を表示する


About This Item

実験式(ヒル表記法):
C22H24FN3O2
CAS番号:
分子量:
381.44
UNSPSCコード:
41116107
NACRES:
NA.24

グレード

pharmaceutical primary standard

APIファミリー

benperidol

メーカー/製品名

EDQM

アプリケーション

pharmaceutical (small molecule)

フォーマット

neat

保管温度

2-8°C

InChI

1S/C22H24FN3O2/c23-17-9-7-16(8-10-17)21(27)6-3-13-25-14-11-18(12-15-25)26-20-5-2-1-4-19(20)24-22(26)28/h1-2,4-5,7-10,18H,3,6,11-15H2,(H,24,28)

InChI Key

FEBOTPHFXYHVPL-UHFFFAOYSA-N

詳細

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

アプリケーション

Benperidol EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包装

この製品は発行元の薬局方による供給としてお届けします。現在の単位量については、EDQM reference substance catalogueをご覧ください。

その他情報

Sales restrictions may apply.

Choose from one of the most recent versions:

試験成績書(COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact カスタマーサポート

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

M Jauss et al.
Movement disorders : official journal of the Movement Disorder Society, 11(6), 726-728 (1996-11-01)
With the tracer [123I]iodobenzamide ([123I]-IBZM), it is possible to image dopamine receptor occupancy with single-photon emission-computed tomography (SPECT). We report follow-up examinations with IBZM-SPECT in neuroleptic malignant syndrome (NMS) to display D2-receptor availability in the acute phase and during the
M Grube et al.
Der Nervenarzt, 70(9), 838-841 (1999-10-16)
In the monotherapeutic treatment of an acute schizophrenic psychoses with butyrophenones (haloperidol and benperidol) we saw immediate leucopenic reactions when the medication was given every day. In literature the risk of butyrophenone-induced blood dyscrasias seems to be underestimated. Therefore we
B Costall et al.
British journal of pharmacology, 116(7), 2989-2999 (1995-12-01)
1. The ability of 5-hydroxytryptophan, 5-HT2 receptor antagonists and typical and atypical neuroleptic agents to modify behavioural responding to aversive situations was investigated in the mouse light/dark test and rat social interaction. 2. The administration of 5-hydroxytryptophan inhibited rat social
S Dammers et al.
Deutsche medizinische Wochenschrift (1946), 120(50), 1739-1742 (1995-12-15)
A 22-year-old oligophrenic patient had on several occasions over several months been given various neuroleptics (haloperidol, benperidol, levomepromazine) for exacerbations of paranoid schizophrenia. For a few days before hospitalization he had become quiet and withdrawn, but on the day of
Susanne Nikolaus et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 44(4), 618-624 (2003-04-08)
A recent investigation showed that intracerebral radioactivity concentrations can reliably be quantified in vivo with a small-animal PET device. The purpose of the current study was to investigate the binding characteristics of the D(2) receptor radioligand (18)F-(3-N-methyl)benperidol ((18)FMB) in rat

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)